Tax-driven sale: NovoCure (NVCR) ex-CMO offloads 1,100 shares to cover RSU taxes

Rhea-AI Filing Summary

NovoCure Ltd former Chief Medical Officer Nicolas Leupin reported an open-market sale of 1,100 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share. According to the disclosure, this sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. Following this transaction, Leupin directly held 102,979 Ordinary Shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leupin Nicolas

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Former Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/04/2026		S		1,100(1)	D	$13.3054(2)	102,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Leupin, Nicolas	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NovoCure (NVCR) report for Nicolas Leupin?

NovoCure (NVCR) reported that former Chief Medical Officer Nicolas Leupin sold 1,100 Ordinary Shares on March 4, 2026. The weighted average sale price was $13.3054 per share, based on multiple trades within a disclosed price range.

Why did Nicolas Leupin sell 1,100 NovoCure (NVCR) shares?

The 1,100 NovoCure (NVCR) shares were sold to cover tax withholding obligations related to the vesting of Restricted Stock Units. The filing states the sale was mandated by the company’s equity incentive award agreement and was not a discretionary trade by Leupin.

What price did Nicolas Leupin receive for the NovoCure (NVCR) share sale?

The reported weighted average sale price was $13.3054 per NovoCure (NVCR) share. The transaction occurred in multiple trades, with prices ranging from $13.21 to $13.445, and the filing aggregated these trades into a single weighted average figure.

How many NovoCure (NVCR) shares does Nicolas Leupin own after this sale?

After selling 1,100 shares, Nicolas Leupin directly held 102,979 Ordinary Shares of NovoCure (NVCR). This post-transaction holding amount is explicitly disclosed as the total number of shares beneficially owned following the reported transaction.

Was the NovoCure (NVCR) insider sale by Nicolas Leupin open-market or private?

The transaction is described as an open-market sale of NovoCure (NVCR) Ordinary Shares. It was executed in multiple trades within a specified price range, with the filing reporting a single weighted average sale price for the entire 1,100-share transaction.

Is the NovoCure (NVCR) insider sale by Nicolas Leupin considered discretionary trading?

The filing states the sale does not represent a discretionary trade by Nicolas Leupin. It was mandated under NovoCure’s equity incentive plans as a “sell to cover” transaction to fund required tax withholding on vesting Restricted Stock Units.